UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The New England journal of medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2020, Volume 75, Issue 2, pp. 133 - 144
proprotein convertase subtilisin/kexin type 9 inhibition | alirocumab | low-density lipoprotein cholesterol | acute coronary syndromes | major adverse cardiovascular events | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Myocardial infarction | Lipoproteins (low density) | Heart attacks | Risk | Cardiovascular disease | Angina | Confidence intervals | Variables | Reduction | Demographics | Randomization | Ischemia | Heart diseases | Statins | Cerebral infarction | Stroke | Health risks | Subtilisin | Apolipoproteins | Angina pectoris | Patients | Coronary artery disease | Cholesterol | Lipoproteins | Kexin | Diabetes | Acute coronary syndromes | Cardiovascular diseases
Journal Article
European heart journal, ISSN 0195-668X, 09/2019, Volume 40, Issue 33, pp. 2801 - 2809
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2019, Volume 74, Issue 9, pp. 1177 - 1186
Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Postoperative Complications - prevention & control | Male | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Acute Coronary Syndrome - surgery | Coronary Artery Bypass | Female | Aged | Drug Therapy, Combination | Myocardial infarction | Therapy | Heart attacks | Cardiovascular disease | Angina | Confidence intervals | Randomization | Ischemia | Surgery | Heart diseases | Statins | Cerebral infarction | Evaluation | Stroke | Mortality | Coronary artery | Health risks | Angina pectoris | Patients | Coronary artery disease | Lipoproteins | Death | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment
Journal Article
European heart journal, ISSN 0195-668X, 10/2013, Volume 34, Issue 40, pp. 3117 - 3127
Aliskiren | Diabetes | Post-discharge | Outcomes | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Prospective Studies | Diabetic Cardiomyopathies - drug therapy | Double-Blind Method | Administration, Oral | Diabetic Cardiomyopathies - mortality | Humans | Middle Aged | Kaplan-Meier Estimate | Hospitalization - statistics & numerical data | Fumarates - administration & dosage | Male | Treatment Outcome | Death, Sudden, Cardiac - etiology | Heart Failure - drug therapy | Cardiotonic Agents - administration & dosage | Renin - antagonists & inhibitors | Female | Amides - administration & dosage | Heart Failure - mortality | Index Medicus | Esc Fasttrack
Journal Article
BMC ophthalmology, ISSN 1471-2415, 05/2005, Volume 5, Issue 1, pp. 10 - 10
Electroretinography | Retinal Vein Occlusion - physiopathology | Prospective Studies | Follow-Up Studies | Tomography, Optical Coherence | Humans | Middle Aged | Intraocular Pressure - physiology | Male | Ischemia - physiopathology | Basement Membrane - surgery | Retinal Vessels | Retinal Vein Occlusion - surgery | Female | Ischemia - surgery | Vitrectomy | Aged | Visual Acuity - physiology | Fluorescein Angiography | Vitreous Body - surgery | Index Medicus
Journal Article
BMC ophthalmology, ISSN 1471-2415, 11/2005, Volume 5, Issue 1, pp. 27 - 27
Glucocorticoids - therapeutic use | Prospective Studies | Humans | Macular Degeneration - complications | Choroidal Neovascularization - therapy | Triamcinolone Acetonide - therapeutic use | Choroidal Neovascularization - etiology | Combined Modality Therapy | Visual Acuity | Pupil | Injections | Pilot Projects | Macular Degeneration - therapy | Vitreous Body | Aged | Hyperthermia, Induced - methods | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Stroke - prevention & control | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Cardiovascular Diseases - mortality | Female | Aged | Glucagon-Like Peptides - therapeutic use | Immunoglobulin Fc Fragments - therapeutic use | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptides - analogs & derivatives | Diabetes Mellitus, Type 2 - complications | Myocardial infarction | Heart attacks | Peptides | Control methods | Glucagon | Clinical trials | Cardiovascular disease | Population studies | Cancer therapies | Evidence-based medicine | Risk factors | Incidence | Randomization | Older people | Hemoglobin | Blood pressure | Diabetes mellitus (non-insulin dependent) | Drug dosages | Glucagon-like peptide 1 | Women | Cerebral infarction | Enzymes | Stroke | Middle age | Diabetes mellitus | Health risks | Hypoglycemia | Risk analysis | Angina pectoris | Disease control | Cholesterol | Thyroid cancer | Agonists | Diabetes | Cardiovascular diseases | Health risk assessment | Index Medicus | Abridged Index Medicus | Medicin och hälsovetenskap
Journal Article
The Lancet (British edition), ISSN 0140-6736, 01/2018, Volume 391, Issue 10117, pp. 205 - 218
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Male | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Coronary Artery Disease - drug therapy | Morbidity | Factor Xa Inhibitors - therapeutic use | Factor Xa Inhibitors - adverse effects | Aged | Coronary Artery Disease - epidemiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Anticoagulants | Aspirin | Stroke | Heart attacks | Mortality | Coronary artery | Clinical trials | Cardiovascular disease | Coronary artery disease | Disease control | Evidence-based medicine | Disease prevention | Coronary vessels | Acute coronary syndromes | Thromboembolism | Health risk assessment | Drug therapy | Heart diseases | Index Medicus | Abridged Index Medicus | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Drug | drug therapy | chemically induced | prevention & control | Coronary Artery Disease | Clinical Medicine | Myocardial Infarction | Platelet Aggregation Inhibitors | adverse effects | mortality | Dose-Response Relationship | therapeutic use
Journal Article